HSPC quiz: Answers
1. What is a key challenge in implementing multidisciplinary teams (MDTs) across nations?
A. Lack of interest from patients
B. Geographic access and time barriers
C. Mandatory federal regulations
D. Overstaffing in hospitals
Correct answer: B. A key challenge in implementing MDTs across nations is geographic access and time barriers.
References:
- Shore, 2022. Addressing challenges and controversies in the management of prostate cancer with multidisciplinary teams. https://doi.org/10.1007/s11523-022-00925-7
- Dasgupta, 2019. Geographical variations in prostate cancer outcomes: A systematic review of international evidence. https://doi.org/10.3389/fonc.2019.00238
- Dundee, 2015. Prostate cancer multidisciplinary care: Improving patient outcomes. https://doi.org/10.1002/tre.468
2. Which of the following treatments is now recommended by guidelines for patients with high-risk biochemically recurrent (BCR) non-metastatic hormone-sensitive (nmHSPC) prostate cancer who are unsuitable for salvage radiation?
A. Apalutamide with or without androgen deprivation therapy (ADT)
B. Darolutamide plus ADT
C. Enzalutamide with or without ADT
D. Radical prostatectomy
Correct answer: C. Enzalutamide plus ADT combination therapy has been shown to be more effective than ADT monotherapy in BCR nmHSPC. Enzalutamide is indicated both as a monotherapy or in combination with ADT.
References:
- Freedland, 2023. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. https://doi.org/10.1056/NEJMoa2303974
- Xtandi (enzalutamide) Prescribing Information, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/203415s025,213674s015lbl.pdf
- Xtandi (enzalutamide) Summary of Product Characteristics, 2025. https://www.ema.europa.eu/en/documents/product-information/xtandi-epar-product-information_en.pdf
3. Which emerging target is under clinical investigation for metastatic hormone-sensitive prostate cancer (mHSPC)?
A. Radioligand therapies targeting DNA repair or PI3K/AKT signaling pathways
B. CAR T-cell therapy targeting antigens such as prostate stem cell antigen
C. KRAS inhibitors targeting mutant forms of the KRAS protein
D. FGFR inhibitors targeting FGFRs and downstream signaling pathways MAPK, STAT, and PI3K/AKT
Correct answer: A. Radioligand therapies targeting DNA repair or PI3K/AKT signaling pathways are emerging therapies under investigation for mHSPC.
Reference:
Smani, 2025. Advances in current treatment paradigms for metastatic hormone-sensitive prostate cancer. https://doi.org/10.3390/jcm14082565
MA-MM-16223, February 2026 This podcast series is sponsored by Astellas. This content includes information about investigational compounds that may be approved by regulatory agencies for specific indications, have been submitted to regulatory agencies for approval for specific indications, or are being studied in clinical trials and do not yet have a regulatory approval or authorization for a specific indication. Information about other potential uses of these products or investigational compounds is intended only for the purposes of medical education and is aimed at increasing the scientific knowledge of healthcare professionals (HCPs), to enhance medical practice and improve patient outcomes and should not be interpreted as intent to promote unapproved uses. Indications and availability of products discussed in this educational meeting may vary in different countries. Please refer to the local summary of product characteristics/prescribing information for details. Astellas prohibits the promotion of unapproved uses and complies with all applicable laws, regulations, and company policies. In expert interviews, podcasts, and panel discussions, the views, thoughts, and opinions expressed belong solely to the speaker(s) and are subject to change without notice. This content is intended for HCPs only. Non-HCPs should not view this educational program and should exit the program as soon as possible.